Marker Therapeutics, Inc.

MRKR · United States

Share price · MRKR

$0.85-0.30 (-25.81%) 3M

close as of 2026-11-18 · 24h delayed · vol 106K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MRKR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Oct 2026+15.4%
  2. 16 Oct 2026+13.0%
  3. 8 Oct 2026-8.7%
  4. 8 Sep 2026+8.5%

    Nothing announced by MRKR that day or the session before.

  5. 24 Aug 2026+7.9%
  6. 21 Aug 2026+13.9%
  7. 5 Aug 2026-7.3%

    Nothing announced by MRKR that day or the session before.

  8. 3 Aug 2026+8.0%

    Nothing announced by MRKR that day or the session before.

  9. 7 Jul 2026+13.5%
  10. 29 Jun 2026+10.6%

Share of unusual movement by asset

For each asset, the share of MRKR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
Six tumor-associated antigensCell therapy
Non-Hodgkin Lymphoma
Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1
WT1, PRAME, survivin (multiple tumor-associated antigens)Cell therapy
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.5M$12M$1.8M-$3.7M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0.8M$2.8M$16M$3.2M-$1.4M operating cash flowreport ↗
2025-Q3$1.2M$2.4M$19M$2.0M-$2.7M operating cash flowreport ↗
2025-Q2$0.9M$4.2M$12M$4.0M-$1.9M operating cash flowreport ↗
2025-Q1$0.3M$3.1M$14M$4.5M-$5.5M operating cash flowreport ↗
2024-Q3$1.9M$3.5M$9.0M$2.3M$1.2M operating cash flowreport ↗
2024-Q2$1.2M$2.3M$7.8M$2.2M-$3.6M operating cash flowreport ↗
2024-Q1$1.2M$2.6M$11M$2.4M-$3.8M operating cash flowreport ↗
2023-Q3$0.3M$2.0M$17M$3.0M-$1.1M operating cash flowreport ↗
2023-Q2$0.8M$2.4M$18M—-$7.1M operating cash flowreport ↗
2023-Q1$4.7M$7.3M$6.4M$5.0M-$5.9M operating cash flowreport ↗
2022-Q3$4.0M$7.3M$18M$6.9M-$7.7M operating cash flowreport ↗
2022-Q2$0.8M$6.6M$26M$9.2M-$0.8M operating cash flowreport ↗
2022-Q1$1.0M$7.0M$29M$9.9M-$12M operating cash flowreport ↗
2021-Q3—$6.8M$49M$12M-$6.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.5M$12M$17M$3.0M-$12M operating cash flowreport ↗

Marker Therapeutics reported full-year 2025 revenue of $3.55M, down 46.1% YoY, with R&D expenses of $11.8M, down 12.4% YoY. Cash and equivalents totaled $17.04M at year-end, and the company reported a net loss of $12.16M. No analyst consensus comparison was provided.

The company guided that existing cash should fund operations through the fourth quarter of 2026, assuming no additional grant funds. Clinical highlights included an updated Phase 1 APOLLO data readout showing a 66% objective response rate in relapsed non-Hodgkin lymphoma with 50% complete responses, a 78% objective response rate in Hodgkin lymphoma, and dose expansion enrollment in relapsed DLBCL. A Nature Medicine publication highlighted multi-antigen targeted T cells in pancreatic cancer with up to an 84.6% disease control rate, and a company-sponsored pancreatic cancer program is expected to initiate in Q2 2026. The company also advanced a manufacturing collaboration with Cellipont Bioservices and appointed Kathryn Penkus Corzo to the Board of Directors.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$6.6M$13M$19M$2.7M-$11M operating cash flowreport ↗
2023-FY$3.3M$10M$15M$2.1M-$16M operating cash flowreport ↗
2022-FY$9.0M$26M$12M$7.5M-$27M operating cash flowreport ↗
2021-FY$1.2M$28M$44M$10M-$27M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2025-11-17ELMS STEVE · directorAward / grant (derivative)84,411——Form 4
2025-11-17Eansor Norman David · directorAward / grant (derivative)84,411——Form 4
2025-11-17Knobil Katharine · directorAward / grant (derivative)84,411——Form 4
2025-11-17ELMS STEVE · directorAward / grant (derivative)137,330——Form 4
2025-11-17Eansor Norman David · directorAward / grant (derivative)137,330——Form 4
2025-11-17Knobil Katharine · directorAward / grant (derivative)137,330——Form 4
2025-10-31Vera Juan · director, Chief Executive OfficerAward / grant (derivative)250,000——Form 4
2025-10-31Corzo Kathryn Penkus · directorAward / grant (derivative)147,611——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 36 reporting institutions held 3.9M shares ($5.1M, 23.4% of shares outstanding).

#InstitutionSharesValue
1NEA Management Company, LLC1,625,678$2.1M
2Blue Owl Capital Holdings LP554,250$721K
3VANGUARD CAPITAL MANAGEMENT LLC389,319$506K
4Aisling Capital Management LP325,370$423K
5RENAISSANCE TECHNOLOGIES LLC175,294$228K
6GEODE CAPITAL MANAGEMENT, LLC160,910$209K
7OSAIC HOLDINGS, INC.93,121$121K
8VANGUARD FIDUCIARY TRUST CO87,269$113K
9LPL Financial LLC83,047$108K
10XTX Topco Ltd63,567$83K
11TWO SIGMA INVESTMENTS, LP61,001$79K
12SUSQUEHANNA INTERNATIONAL GROUP, LLP48,780$63K
13JANE STREET GROUP, LLC36,303$47K
14UBS Group AG32,369$42K
15Invst, LLC29,000$38K